Drug Trial Radar · NCT02832063
Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
372
Actual
Start
Aug 2016
Primary completion
Jul 19, 2017
Study completion Jul 19, 2017
Sponsor
- Lead sponsor
- AOBiome LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
Conditions
- Acne Vulgaris
Interventions
B244Biological
4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
PlaceboBiological
4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment RelatedAdverse EventsTime frame: 16 weeks
- Change in Inflammatory and Non-inflammatory Lesion CountTime frame: 12 weeks
- Number of Participants Demonstrating Efficacy Measured by Investigator Global Assessment SuccessTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Science37
Culver City, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.